Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes.

Blevins T, Han J, Nicewarner D, Chen S, Oliveira JH, Aronoff S

Postgraduate medicine1 May 2010Cited by 18 (Europe PMC)

PMID20463421DOI10.3810/pgm.2010.05.2149PepBankPUB-20463421

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide was non-inferior to insulin for HbA1c reduction at 26 weeks.
In plain wordsIn patients with diabetes, exenatide was non-inferior to insulin for HbA1c reduction at 26 weeks.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHbA1c at 26 weeks
Study
n: not reported in source
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.2%
exenatide
HbA1c change
−1.1%
insulin
Source sentences
Summary
At 26 weeks, glycemic control with exenatide (-1.2% HbA1c) was non-inferior to insulin (-1.1%; exenatide vs insulin; P = 0.09).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 4 randomized, open-label, comparator-controlled clinical trials in 1423 patients with type 2 diabetes followed for 16 to 52 weeks were pooled and analyzed.
Report a problemFND-2046342101
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide and insulin produced similar HbA1c reductions, greatest in the highest baseline tertile.
In plain wordsIn patients with diabetes, exenatide and insulin reduced HbA1c similarly, with the largest reductions among those with the highest starting levels.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHbA1c reduction by baseline tertile
Study
n: not reported in source
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In a tertile analysis of HbA1c reduction from baseline, exenatide induced similar reductions compared with insulin, with the greatest reductions observed in the tertile with the highest baseline HbA1c (9%-12.7%).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 4 randomized, open-label, comparator-controlled clinical trials in 1423 patients with type 2 diabetes followed for 16 to 52 weeks were pooled and analyzed.
Report a problemFND-2046342102
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced weight while insulin increased weight.
In plain wordsIn patients with diabetes, weight fell with exenatide and rose with insulin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight change
Study
n: not reported in source
Comparator
Insulin
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Weight change
−2 kg
exenatide
Weight increase
1.8 kg
insulin
Source sentences
Summary
Exenatide treatment induced weight loss (-2 kg) and reduced systolic blood pressure (SBP) from baseline (SBP, -4.9 mm Hg, exenatide vs insulin; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In contrast, insulin treatment increased body weight (1.8 kg) and decreased SBP by -0.4 mm Hg.
Summary · context
Data from 4 randomized, open-label, comparator-controlled clinical trials in 1423 patients with type 2 diabetes followed for 16 to 52 weeks were pooled and analyzed.
Report a problemFND-2046342103
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced systolic blood pressure more than insulin.
In plain wordsIn patients with diabetes, exenatide reduced systolic blood pressure more than insulin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Insulin
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
SBP change
−4.9 mm Hg
exenatide
SBP change
−0.4 mm Hg
insulin
Source sentences
Summary
Exenatide treatment induced weight loss (-2 kg) and reduced systolic blood pressure (SBP) from baseline (SBP, -4.9 mm Hg, exenatide vs insulin; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In contrast, insulin treatment increased body weight (1.8 kg) and decreased SBP by -0.4 mm Hg.
Summary · context
Data from 4 randomized, open-label, comparator-controlled clinical trials in 1423 patients with type 2 diabetes followed for 16 to 52 weeks were pooled and analyzed.
Report a problemFND-2046342104
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, weight loss occurred in 70% with exenatide versus 21% with insulin.
In plain wordsIn patients with diabetes, 70% lost weight with exenatide versus 21% with insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePatients with weight loss
Study
n: not reported in source
Comparator
Insulin
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Weight loss responders
70%
exenatide
Weight loss responders
21%
insulin
Source sentences
Summary
Overall, about 3-fold more exenatide-treated patients (70%) experienced weight loss compared with those treated with insulin (21%).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 4 randomized, open-label, comparator-controlled clinical trials in 1423 patients with type 2 diabetes followed for 16 to 52 weeks were pooled and analyzed.
Report a problemFND-2046342105
06HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, nocturnal mild-to-moderate hypoglycemia was less frequent with exenatide than insulin.
In plain wordsIn patients with diabetes, mild-to-moderate low blood sugar at night occurred less often with exenatide than insulin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNocturnal mild-to-moderate hypoglycemia
Study
n: not reported in source
Comparator
Insulin
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Measurements
Nocturnal hypoglycemia
15%
exenatide
Nocturnal hypoglycemia
29%
insulin
Nocturnal hypoglycemia difference
−14%
exenatide minus insulin
Source sentences
Summary
Occurrence of nocturnal mild-to-moderate hypoglycemia was lower with exenatide (15%) treatment than with insulin (29%; difference, -14; [95% CI, -18, -9.8]).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from 4 randomized, open-label, comparator-controlled clinical trials in 1423 patients with type 2 diabetes followed for 16 to 52 weeks were pooled and analyzed.
Report a problemFND-2046342106
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, the exenatide effect on HbA1c persisted at 52 weeks.
In plain wordsIn patients with diabetes, the HbA1c reduction during exenatide treatment persisted at 52 weeks.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSustained HbA1c effect
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Effects of exenatide on HbA1c and weight were sustained at 52 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
At 26 weeks, glycemic control with exenatide (-1.2% HbA1c) was non-inferior to insulin (-1.1%; exenatide vs insulin; P = 0.09).
Summary · context
Data from 4 randomized, open-label, comparator-controlled clinical trials in 1423 patients with type 2 diabetes followed for 16 to 52 weeks were pooled and analyzed.
Report a problemFND-2046342107
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, the exenatide effect on weight persisted at 52 weeks.
In plain wordsIn patients with diabetes, weight loss during exenatide treatment persisted at 52 weeks.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSustained weight effect
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Effects of exenatide on HbA1c and weight were sustained at 52 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Exenatide treatment induced weight loss (-2 kg) and reduced systolic blood pressure (SBP) from baseline (SBP, -4.9 mm Hg, exenatide vs insulin; P < 0.0001).
Summary · context
Data from 4 randomized, open-label, comparator-controlled clinical trials in 1423 patients with type 2 diabetes followed for 16 to 52 weeks were pooled and analyzed.
Report a problemFND-2046342108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.